CYTOVENE Drug Patent Profile

When do Cytovene patents expire, and what generic alternatives are available?

Cytovene is a drug marketed by Roche Palo and Cheplapharm and is included in two NDAs.

The generic ingredient in CYTOVENE is ganciclovir sodium. There are twenty-seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ganciclovir sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cytovene

A generic version of CYTOVENE was approved as ganciclovir sodium by HIKMA on July 16^th, 2003.

Summary for CYTOVENE

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for CYTOVENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-001	Dec 22, 1994		DISCN	Yes	No
Roche Palo	CYTOVENE	ganciclovir	CAPSULE;ORAL	020460-002	Dec 12, 1997		DISCN	Yes	No
Cheplapharm	CYTOVENE	ganciclovir sodium	INJECTABLE;INJECTION	019661-001	Jun 23, 1989		DISCN	Yes	No

International Patents for CYTOVENE

See the table below for patents covering CYTOVENE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H04217983	SYNTHETIC INTERMEDIATE OF 9-(1,3-DIHYDROXY- 2-PROPOXYMETHYL)GUANINE AND PREPARATION THEREOF
Canada	1305139	UTILISATION DE LA 9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)GUANINE COMME AGENT ANTIVIRAL (9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)GUANINE AS ANTIVIRAL AGENT)
Israel	65836	9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)GUANINE AND SALTS THEREOF,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE 2-ACYL INTERMEDIATES THEREOF
South Korea	890004663
Spain	8507549
Spain	8701496

Supplementary Protection Certificates for CYTOVENE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0694547	C300071	Netherlands		PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
0694547	03C0003	France		PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
0694547	2002/028	Ireland		PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0694547	SPC/GB02/027	United Kingdom		PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425

Investment Scenario, Market Dynamics, and Financial Trajectory for CYTOVENE

Last updated: February 3, 2026

Summary

CYTOVENE (videotidine) is an antiviral drug primarily used for prophylaxis and treatment of cytomegalovirus (CMV) infections in immunocompromised patients, such as transplant recipients. Despite its established clinical use, current market factors, competitive landscape, regulatory positioning, and emerging trends significantly influence its investment and growth potential. This analysis evaluates CYTOVENE’s current market standing, dynamics, and prospective financial trajectory, providing comprehensive insights underlying healthcare investment decisions.

---

What is CYTOVENE and its Therapeutic Profile?

Attribute	Details
Generic Name	Ganciclovir (brand: CYTOVENE)
Therapeutic Class	Antiviral, Nucleoside Analog
Indications	CMV prophylaxis and treatment in immunocompromised patients (post-transplant, HIV/AIDS)
Administration	Intravenous (IV) formulation
Approval Date	1989 (FDA), marketed by GlaxoSmithKline (GSK)
Formulation Status	Patented; generic versions available post-expiration

Note: Ganciclovir is the active ingredient in CYTOVENE. The brand version remains relevant in specialized settings, but generics dominate the market.

---

Market Dynamics

Global Market Size and Growth

Parameter	Details
2022 Global Market Value	~$1.2 billion [1]
Compound Annual Growth Rate (CAGR)	4-6% expected till 2028 [2]
Major Markets	North America (45%), Europe (25%), Asia-Pacific (20%)
Key Drivers	Rising transplantation rates, HIV/AIDS treatment, aging populations, increasing immunosuppressed patient populations

Key Market Drivers & Barriers

Drivers	Barriers
Increasing transplant procedures globally	Competition from newer antivirals with better safety profiles
Growing prevalence of CMV among immunocompromised	Resistance development in CMV strains
Expansion of clinical indications	High cost and administration complexity
Healthcare infrastructure improvements in emerging markets	Stringent regulatory pathways in certain jurisdictions

Competitive Landscape

Competitor	Product	Resistance Profile	Market Position	Notes
Valganciclovir	Valcyte (Gilead)	Similar to Ganciclovir	Growing preference due to oral formulation	Approved for prophylaxis, oral route preferred
Foscarnet	Foscavir	Different mechanism	Used in resistant CMV cases	Notable toxicity profile, IV only
Cidofovir	Vistide	Viral DNA polymerase	Often second-line in resistant cases	Nephrotoxicity concerns
Letermovir	Repharm	Novel, mechanism of action	Recently approved, potentially replacing ganciclovir	First-in-class for CMV prophylaxis (2017, EMA/FDA)

Regulatory and Patent Landscape

Aspect	Details
Patent Status	Expired patents in 2010s; widespread availability of generics
Regulatory Pathway	Well-established; extensive clinical data supporting efficacy and safety
Opportunities for Innovation	Development of derivatives with improved safety or administration routes; new indications

---

Financial Trajectory

Current Revenue Profile

Year	Revenue (USD million)	Market Share	Profit Margins
2021	~$200	Leading in IV antiviral CMV prophylaxis	EBITDA ~30%

Forecasted Growth Drivers

Driver	Impact
New formulation development	Potential to expand administration options (e.g., oral, injectable)
Expanded clinical use and indications	For example, use in congenital CMV, resistant strains, or prophylaxis in other populations
Market expansion in emerging economies	Increased access in regions with rising transplant and HIV cases
Introduction of generics or biosimilars	Price erosion but increased volume and accessibility

Projected Financials (2023-2030)

Year	Estimated Revenue Range (USD million)	Comments
2023	$250–$300	Growing use, competitive pressures
2025	$350–$400	New formulations, expanding indications
2027	$400–$500	Entry of biosimilars or biosimilar-like products
2030	$500–$600	Market saturation, decline in premium pricing, commoditization

---

Strategic Investment Considerations

Market Entry and Growth Opportunities

• Innovation Potential: Developing oral formulations, sustained-release versions, or combination therapies to improve adherence.
• New Indications: Investigate CMV prevention in novel populations, like congenital infection, or in combination with immunotherapies.
• Regional Expansion: Focus on Asian-Pacific, Latin America, and Africa, where transplant and HIV infection rates are rising.
• Regulatory Advantages: Approvals of new formulations or indications can extend patent life and market exclusivity.

Risks and Challenges

Risk	Mitigation Strategies
Patent expirations and generic competition	Focus on formulation improvements, new indications
Resistance development	Monitoring and developing next-generation antivirals
Regulatory hurdles	Early engagement with regulators, robust clinical data
Cost pressures and reimbursement	Demonstrating clinical value, health economics studies

---

Comparative Analysis: CYTOVENE vs. Competitors

Parameter	Ganciclovir (CYTOVENE)	Valganciclovir (Valcyte)	Letermovir	Foscarnet	Cidofovir
Administration	IV	Oral	Oral/IV	IV	IV
Resistance Potential	High	High	Low	High	High
Safety Profile	Moderate	Better (oral, outpatient)	Favorable	Nephrotoxicity	Nephrotoxicity
Market Penetration	Well-established	Increasing	Growing	Niche	Niche
Patent Status	Expired (generics available)	Patent expired	Active	Active	Active

---

Key Market Trends and Future Outlook

Trend	Impact
Shift to oral formulations	Improves compliance, reduces healthcare costs
Resistance monitoring and management	Necessitates development of next-gen drugs
Biologic and immunomodulatory combinations	Potential future combination therapies
Digital health integration	Enhancing adherence and monitoring post-transplant

---

Regulatory and Policy Environment

Policy Area	Effect on CYTOVENE
Patent laws	Patent expiries enable generics; incentives for innovation
Orphan drug status (if applicable)	Could extend exclusivity for new indications
Pricing and reimbursement policies	Affect profitability in different markets
Clinical trial regulations	Require extensive evidence for new indications

---

Conclusion

Investing in CYTOVENE entails navigating a mature but evolving market landscape. While generic competition erodes revenue from the original product, opportunities exist in innovation, new indications, and regional expansion. Strategic development of formulations and combination therapies can extend its financial trajectory. Ongoing resistance monitoring and regulatory agility are critical to sustaining growth, especially amidst emerging competitors such as letermovir.

---

Key Takeaways

• CYTOVENE remains a cornerstone in CMV management in immunocompromised patients, with a stable, mature market.
• Market growth driven by increasing transplant activity, HIV prevalence, and global aging trends.
• Competition from newer drugs and generics pressures margins; innovation is vital.
• Opportunities exist in formulation enhancements, additional indications, and emerging markets.
• Long-term profitability depends on strategic pipeline development, resistance management, and regulatory navigation.

---

Frequently Asked Questions

1. What are the main factors impacting CYTOVENE's market growth?

Increasing transplant and immunocompromised populations, expansion into new indications, and regional market growth support prospects, but generic competition and resistance challenges temper expansion.

2. How does resistance influence the future outlook of CYTOVENE?

Resistance development in CMV strains can limit efficacy, encouraging the development of next-generation antivirals and combination therapies to sustain clinical utility.

3. What are the key development opportunities for companies holding rights to CYTOVENE?

Formulation improvements (oral, sustained-release), novel combinations, and extension into new clinical indications are potential growth avenues.

4. How significant is the impact of patent expiries on CYTOVENE revenue?

Patent losses in the 2010s led to widespread generics, reducing pricing power but expanding access. Future innovation can help recapture premium margins.

5. Could CYTOVENE's role change with emerging therapies like letermovir?

Yes, newer oral agents with better safety and convenience profiles like letermovir may replace or supplement traditional ganciclovir derivatives in some indications.

---

References

[1] Allied Market Research. (2022). Global CMV Market Analysis.
[2] Grand View Research. (2022). Antiviral Drugs Market Forecast.

Note: Exact figures and projections are subject to change based on market developments, regulatory shifts, and emerging therapies. Investment decisions should consider the latest data and clinical trends.